ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HALO Halozyme Therapeutics Incorporated

49.50
-0.12 (-0.24%)
Jun 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,418,017
Bid Price 29.27
Ask Price 52.00
News (1)
Day High 49.77

Low
32.78

52 Week Range

High
53.00

Day Low 48.495
Company Name Stock Ticker Symbol Market Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -0.24% 49.50 00:00:06
Open Price Low Price High Price Close Price Prev Close
49.095 48.495 49.77 49.50 49.62
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
18,718 1,418,017 $ 48.97 $ 69,437,737 - 32.78 - 53.00
Last Trade Time Type Quantity Stock Price Currency
16:20:29 1 $ 50.45 USD

Halozyme Therapeutics Incorporated Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.28B 126.82M - 829.25M 281.59M 2.22 22.31
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Halozyme Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No HALO Message Board. Create One! See More Posts on HALO Message Board See More Message Board Posts

Historical HALO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week51.4051.6648.49550.351,657,580-1.90-3.70%
1 Month45.3653.0042.0547.591,332,7384.149.13%
3 Months40.3053.0037.7343.501,060,5299.2022.83%
6 Months42.6253.0033.1539.601,235,8566.8816.14%
1 Year34.0253.0032.7839.321,101,05615.4845.50%
3 Years43.5659.4629.8541.291,109,5035.9413.64%
5 Years15.8359.4612.7135.431,205,14933.67212.70%

Halozyme Therapeutics Description

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Your Recent History

Delayed Upgrade Clock